Immunitybio Stock Analysis
| IBRX Stock | USD 6.05 0.41 7.27% |
IPO Date 28th of July 2015 | 200 Day MA 2.7409 | 50 Day MA 3.3106 | Beta 0.017 |
At this time, Immunitybio's Short and Long Term Debt Total is fairly stable compared to the past year. Net Debt is likely to rise to about 435.6 M in 2026, whereas Short Term Debt is likely to drop slightly above 8.2 M in 2026. With a high degree of financial leverage come high-interest payments, which usually reduce Immunitybio's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 1.18 | Current Value 1.24 | Quarterly Volatility 0.63752192 |
Given that Immunitybio's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Immunitybio is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Immunitybio to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Immunitybio is said to be less leveraged. If creditors hold a majority of Immunitybio's assets, the Company is said to be highly leveraged.
At this time, Immunitybio's Common Stock Total Equity is fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 3.5 B in 2026, despite the fact that Total Stockholder Equity is likely to grow to (418.2 M). . Price Earnings To Growth Ratio is likely to rise to 0.08 in 2026, whereas Price To Sales Ratio is likely to drop 132.26 in 2026. Immunitybio is undervalued with Real Value of 7.2 and Target Price of 11.8. The main objective of Immunitybio stock analysis is to determine its intrinsic value, which is an estimate of what Immunitybio is worth, separate from its market price. There are two main types of Immunitybio's stock analysis: fundamental analysis and technical analysis.
The Immunitybio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immunitybio is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Immunitybio Stock trading window is adjusted to America/New York timezone.
Immunitybio | Build AI portfolio with Immunitybio Stock |
Immunitybio Stock Analysis Notes
About 66.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.41. Immunitybio had not issued any dividends in recent years. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. To learn more about Immunitybio call Richard Adcock at 844 696 5235 or check out https://immunitybio.com.Immunitybio Quarterly Total Revenue |
|
Immunitybio Investment Alerts
| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 82.18 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: A Look At ImmunityBio Valuation As ResQ215B Phase 2 Trial Progresses |
Immunitybio Largest EPS Surprises
Earnings surprises can significantly impact Immunitybio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2020-11-09 | 2020-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2020-05-11 | 2020-03-31 | -0.17 | -0.19 | -0.02 | 11 |
Immunitybio Environmental, Social, and Governance (ESG) Scores
Immunitybio's ESG score is a quantitative measure that evaluates Immunitybio's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Immunitybio's operations that may have significant financial implications and affect Immunitybio's stock price as well as guide investors towards more socially responsible investments.
Immunitybio Stock Institutional Investors
| Shares | Citigroup Inc | 2025-06-30 | 2.5 M | Tang Capital Management Llc | 2025-06-30 | 2.3 M | Susquehanna International Group, Llp | 2025-06-30 | 1.9 M | Northern Trust Corp | 2025-06-30 | 1.8 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.8 M | Royal Bank Of Canada | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 1.2 M | Jpmorgan Chase & Co | 2025-06-30 | 1.1 M | Bsc Private Wealth Management, Llc | 2025-06-30 | 846.4 K | Vanguard Group Inc | 2025-06-30 | 21.8 M | Blackrock Inc | 2025-06-30 | 17.8 M |
Immunitybio Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.56 B.Immunitybio Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.36) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | 0.76 | 0.80 |
Management Efficiency
Immunitybio has return on total asset (ROA) of (0.3689) % which means that it has lost $0.3689 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.80 in 2026, whereas Return On Tangible Assets are likely to drop (1.36) in 2026. At this time, Immunitybio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 28.8 M in 2026, whereas Total Assets are likely to drop slightly above 299.1 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.81) | (0.76) | |
| Tangible Book Value Per Share | (0.83) | (0.79) | |
| Enterprise Value Over EBITDA | (7.30) | (7.67) | |
| Price Book Value Ratio | (3.28) | (3.45) | |
| Enterprise Value Multiple | (7.30) | (7.67) | |
| Price Fair Value | (3.28) | (3.45) | |
| Enterprise Value | 3.3 B | 5 B |
The strategic initiatives led by Immunitybio's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 7th of February, Immunitybio retains the Risk Adjusted Performance of 0.1886, market risk adjusted performance of 2.27, and Downside Deviation of 4.83. Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunitybio Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Immunitybio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunitybio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunitybio Outstanding Bonds
Immunitybio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunitybio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunitybio bonds can be classified according to their maturity, which is the date when Immunitybio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Immunitybio Predictive Daily Indicators
Immunitybio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunitybio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1.4 M | |||
| Daily Balance Of Power | 0.8723 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 5.85 | |||
| Day Typical Price | 5.91 | |||
| Price Action Indicator | 0.41 | |||
| Period Momentum Indicator | 0.41 |
Immunitybio Corporate Filings
8K | 26th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 15th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 14th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 29th of December 2025 Other Reports | ViewVerify | |
F3 | 16th of December 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 15th of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Immunitybio Forecast Models
Immunitybio's time-series forecasting models are one of many Immunitybio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunitybio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Immunitybio Bond Ratings
Immunitybio financial ratings play a critical role in determining how much Immunitybio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Immunitybio's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (2.72) | Unlikely Manipulator | View |
Immunitybio Debt to Cash Allocation
As Immunitybio follows its natural business cycle, the capital allocation decisions will not magically go away. Immunitybio's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity.Immunitybio Total Assets Over Time
Immunitybio Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Immunitybio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Immunitybio Debt Ratio | 124.0 |
Immunitybio Corporate Bonds Issued
Immunitybio Short Long Term Debt Total
Short Long Term Debt Total |
|
About Immunitybio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunitybio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunitybio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunitybio. By using and applying Immunitybio Stock analysis, traders can create a robust methodology for identifying Immunitybio entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (25.25) | (26.51) | |
| Operating Profit Margin | (21.01) | (22.06) | |
| Net Loss | (25.24) | (26.51) | |
| Gross Profit Margin | (239.87) | (227.88) |
Current Immunitybio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunitybio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunitybio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 11.8 | Strong Buy | 5 | Odds |
Most Immunitybio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunitybio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunitybio, talking to its executives and customers, or listening to Immunitybio conference calls.
Immunitybio Stock Analysis Indicators
Immunitybio stock analysis indicators help investors evaluate how Immunitybio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunitybio shares will generate the highest return on investment. By understating and applying Immunitybio stock analysis, traders can identify Immunitybio position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 265.8 M | |
| Long Term Debt | 461.9 M | |
| Common Stock Shares Outstanding | 700.4 M | |
| Total Stockholder Equity | -489.1 M | |
| Total Cashflows From Investing Activities | -12.2 M | |
| Property Plant And Equipment Net | 170.5 M | |
| Cash And Short Term Investments | 149.8 M | |
| Cash | 143.4 M | |
| Accounts Payable | 6.7 M | |
| Net Debt | 360.7 M | |
| 50 Day M A | 3.3106 | |
| Total Current Liabilities | 54.9 M | |
| Other Operating Expenses | 358.9 M | |
| Non Current Assets Total | 198.3 M | |
| Non Currrent Assets Other | 12 M | |
| Stock Based Compensation | 34.4 M |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.